Free Newsletter
Copaxone disappoints at higher dose
Shares of Israel's Teva Pharmaceuticals slid after the company announced that a late-stage trial of a higher dose of its MS drug Copaxone did not perform better than a standard dose. Report
Shares of Israel's Teva Pharmaceuticals slid after the company announced that a late-stage trial of a higher dose of its MS drug Copaxone did not perform better than a standard dose. Report
Click here to get the FierceBiotech email newsletter for FREE!
Be the first to comment